Cargando…

Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment

Multikinase inhibitors (MKIs) have been the only first-line treatment for advanced hepatocellular carcinoma (HCC) for more than a decade, until the approval of immune checkpoint inhibitors (ICIs). Moreover, the combination regimen of atezolizumab (anti-programmed cell death protein ligand 1 antibody...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Ze-Long, Liu, Jing-Hua, Staiculescu, Daniel, Chen, Jiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Immunotherapy in Hepatocellular Carcinoma: a New Kid on the Block
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150670/ https://www.ncbi.nlm.nih.gov/pubmed/34104226 http://dx.doi.org/10.1177/17588359211018026

Ejemplares similares

Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab
por: Hsu, Chiun, et al.
Publicado: (2021)

Development and Validation of Nomograms to Predict the Prognosis of Patients With Unresectable Hepatocellular Carcinoma Receiving Transarterial Chemoembolization
por: Zhao, Dongxu, et al.
Publicado: (2023)

Recent Update on Immunotherapy and Its Combination With Interventional Therapies for Hepatocellular Carcinoma
por: Huang, Jin-Tao, et al.
Publicado: (2022)

Effectiveness of c-TACE Combined With Sorafenib Versus c-TACE Monotherapy in Advanced Hepatocellular Carcinoma: A Retrospective Study
por: Liu, Shanshan, et al.
Publicado: (2023)

Serum levels of preoperative α-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation
por: Wan, Ping, et al.
Publicado: (2014)

Role of Plasma methylated SEPT9 for Predicting Microvascular Invasion and Tumor Proliferation in Hepatocellular Carcinoma
por: Huang, Fei, et al.
Publicado: (2022)

Thema: Ziekepietjes
por: Overduin, Carla
Publicado: (2022)

Baseline characteristics associated with survival in patients with hepatocellular carcinoma
por: Aslanov, Seymur, et al.
Publicado: (2021)

Artificial intelligence method to predict overall survival of hepatocellular carcinoma
por: Simsek, Cem, et al.
Publicado: (2021)

Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2020)

Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2022)

Clinical outcomes for nasopharyngeal cancer with intracranial extension after taxane-based induction chemotherapy and concurrent chemo-radiotherapy in the modern era
por: Ghosh-Laskar, Sarbani, et al.
Publicado: (2020)

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
por: Song, Xuyang, et al.
Publicado: (2023)

Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study
por: Lee, Ji Hyun, et al.
Publicado: (2022)

Efficacy of profound versus moderate neuromuscular blockade in enhancing postoperative recovery after laparoscopic donor nephrectomy: A randomised controlled trial
por: Bruintjes, Moira H.D., et al.
Publicado: (2019)

Early experience in MRI-guided therapies of prostate cancer: HIFU, laser and photodynamic treatment
por: Da Rosa, M.R., et al.
Publicado: (2011)

The Significance of the Presence of Lactic Acid, and of Deficiency or Absence of Free Hydrochloric Acid, in the Gastric Contents as a Means of Diagnosis
Publicado: (1907)

Bronchoscopic Diagnosis of Carcinoma of the Lung
por: Scarff, Gordon
Publicado: (1936)

Primary Carcinoma of the Lung Radiologically Considered
por: Bush, Gilbert B.
Publicado: (1936)

The Treatment of Carcinoma of the Lung
por: Wood, Duncan
Publicado: (1936)

The Pathological Aspect
por: Taylor, Arthur L.
Publicado: (1936)

Clinical Features
por: Perry, C. Bruce
Publicado: (1936)

Nasopharyngeal carcinoma – Improving cure with technology and clinical trials
por: Tsang, Raymond K.
Publicado: (2020)

Real time in-vivo miniature endoscopic surveillance system for imaging of nasopharynx
por: Lim, Chwee Ming, et al.
Publicado: (2020)

Dysphagia after chemo-radiation for nasopharyngeal cancer: A scoping review
por: Fong, Raymond, et al.
Publicado: (2020)

Repeated exposure to fractional CO(2) laser delays squamous cell carcinoma formation and prevents clinical and subclinical photodamage visualized by line‐field confocal optical coherence tomography and histology
por: Olesen, Uffe H., et al.
Publicado: (2022)

Laser therapy as a treatment for chronic radiation fibrosis
por: Wilson, Britney, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
por: Abd El Aziz, Mohamed A., et al.
Publicado: (2020)

IMMU-14. IMMUNE CHECKPOINT INHIBITOR THERAPY FOR TREATMENT OF SYNCHRONOUS CANCERS IN PAEDIATRIC PATIENTS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY
por: Henderson, Jacob, et al.
Publicado: (2020)

Effects of combining immune checkpoint inhibitors and anti-angiogenic agents on bone metastasis in non-small cell lung cancer patients
por: Xie, Xiaohong, et al.
Publicado: (2023)

Y-90 Microshperes in the Treatment of Unresectable Hepatocellular Carcinoma
por: Al-Kalbani, Abdullah, et al.
Publicado: (2008)

The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review
por: Ke, Qiao, et al.
Publicado: (2022)

MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy
por: Jiang, Xiaoyu, et al.
Publicado: (2020)

Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma
por: Bersanelli, Melissa, et al.
Publicado: (2023)

Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
por: Sise, Meghan E, et al.
Publicado: (2023)

Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma
por: Ma, Yuxiang, et al.
Publicado: (2021)

Anything for Billy /
por: McMurtry, Larry
Publicado: (1989)

Current perspectives on novel systemic therapeutic agents beyond immune checkpoint inhibition in metastatic urothelial carcinoma
por: Choi, Hoon, et al.
Publicado: (2020)

Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma
por: Weppler, Alison M, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_15o868sm035791b7v2prrl2m49